Barinthus Biotherapeutics Approves Key Proposals at AGM

Barinthus Biotherapeutics ( (BRNS) ) has issued an announcement.

On June 10, 2025, Barinthus Biotherapeutics held its Annual General Meeting where all proposed matters were approved, including the re-election of directors and the appointment of auditors. The meeting also covered financial matters such as the approval of the directors’ remuneration policy and the decision not to pay dividends for the fiscal year ending December 31, 2024.

The most recent analyst rating on (BRNS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.

Spark’s Take on BRNS Stock

According to Spark, TipRanks’ AI Analyst, BRNS is a Neutral.

Barinthus Biotherapeutics is in a critical growth phase, with strong revenue increases but significant financial challenges impacting its overall score. The technical indicators provide a slightly positive outlook in the short term, while valuation metrics highlight the inherent risks associated with the company’s current financial position.

To see Spark’s full report on BRNS stock, click here.

More about Barinthus Biotherapeutics

Barinthus Biotherapeutics plc operates in the biotherapeutics industry, focusing on the development and commercialization of innovative therapies. The company is involved in advancing biotherapeutic products that address unmet medical needs.

Average Trading Volume: 34,064

Technical Sentiment Signal: Sell

Current Market Cap: $40.14M

Learn more about BRNS stock on TipRanks’ Stock Analysis page.